Skip to main content
. Author manuscript; available in PMC: 2014 Dec 10.
Published in final edited form as: J Control Release. 2013 May 9;172(2):10.1016/j.jconrel.2013.04.025. doi: 10.1016/j.jconrel.2013.04.025

Figure 3. Representative bile chromatograms.

Figure 3

Representative bile chromatograms for the Taxotere and Procet 8 treatment groups are displayed. The docetaxel hydroxy-tert-butyl carbamate (HDTX, M2), docetaxel (DTX), putative cyclic hydroxyoxazolidinone diastereomer metabolites (M1/M3), and paclitaxel (PTX) IS peaks are labeled on the chromatograms. For metabolite structures refer to [16].

Cumulative biliary DTX and HDTX excretion were approximately 17 and 6 fold greater for the Taxotere treated animals in comparison to Procet 8 treated animals (12.02 ± 8.15 vs. 0.72±0.54 % injected dose for DTX, and 17.15 ± 3.71 vs. 2.93+0.72 % injected dose for HDTX, mean ± SD), respectively (Fig. 4 and 5). However, the percentage of the total 8h biliary metabolites excreted as HDTX, %HDTX=total HDTX/(total HDTX+ total DTX)*100, did not vary significantly between the Taxotere and Procet 8 treatment groups, 82±12% vs. 62±16%, respectively. The similarity of the biliary metabolic profile for both treatment groups, supports scomparable metabolism of the active DTX following prodrug hydrolysis.